Individual variation of hormonal recovery after cessation of luteinizing hormone-releasing hormone agonist therapy in men receiving long-term medical castration therapy for prostate cancer

By Kobayashi Takashi   Nishizawa Koji   Mitsumori Kenji  

Scandinavian Journal of Urology and Nephrology, Vol. 40, Iss. 3, 2006-05 ,pp. : 198-203

Informa Healthcare

Access to resources Recommend Favorite

Protection of the germinal epithelium in the rat from the cytotoxic effects of chemotherapy by a luteinizing hormone-releasing hormone agonist and antiandrogen therapy

By Cespedes R.D.   Peretsman S.J.   Thompson I.M.   Jackson C.  

Urology, Vol. 46, Iss. 5, 1995-11 ,pp. : 688-691

Elsevier

Access to resources Recommend Favorite

Prospective determination of the hormonal response after cessation of luteinizing hormone-releasing hormone agonist treatment in patients with prostate cancer - implications for dosing schedule and neoadjuvant study consideration

By Hall M.C.   Fritzsch R.J.   Sagalowsky A.I.   Ahrens A.   Petty B.   Roehrborn C.G.  

Urology, Vol. 53, Iss. 5, 1999-05 ,pp. : 898-902

Elsevier

Access to resources Recommend Favorite

Squamous cell carcinoma of the prostate: a transformation from adenocarcinoma after the use of a luteinizing hormone-releasing hormone agonist and flutamide

By Braslis K.G.   David R.C.   Nelson E.   Civantos F.   Soloway M.S.  

Urology, Vol. 45, Iss. 2, 1995-02 ,pp. : 329-331

Elsevier

Access to resources Recommend Favorite

Luteinizing hormone-releasing hormone antagonist cetrorelix as primary single therapy in patients with advanced prostatic cancer and paraplegia due to metastatic invasion of spinal cord

By Gonzalez-Barcena D.   Vadillo-Buenfil M.   Cortez-Morales A.   Fuentes-Garcia M.   Cardenas-Cornejo I.   Comaru-Schally A.M.   Schally A.V.  

Urology, Vol. 45, Iss. 2, 1995-02 ,pp. : 275-281

Elsevier

Access to resources Recommend Favorite